Aligos Therapeutics, Inc.
ALGS
$5.60
-$0.16-2.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -75.96M | -90.32M | -24.19M | -86.46M | -74.18M |
| Total Depreciation and Amortization | 1.08M | 1.08M | 930.00K | 914.00K | 942.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.53M | 2.91M | -55.45M | 8.15M | 4.80M |
| Change in Net Operating Assets | -21.82M | 1.61M | -3.79M | -1.76M | -6.48M |
| Cash from Operations | -94.17M | -84.72M | -82.50M | -79.16M | -74.92M |
| Capital Expenditure | -355.00K | -463.00K | -437.00K | -373.00K | -206.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 105.95M | 41.64M | -37.39M | -15.46M | -52.91M |
| Cash from Investing | 105.59M | 41.17M | -37.83M | -15.83M | -53.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -91.00K | -76.00K | -14.00K | -54.00K | -49.00K |
| Issuance of Common Stock | 362.00K | 126.00K | 101.87M | 101.88M | 101.88M |
| Repurchase of Common Stock | -43.00K | -219.00K | -219.00K | -219.00K | -176.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 228.00K | -169.00K | 101.64M | 101.61M | 101.66M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.65M | -43.72M | -18.69M | 6.62M | -26.38M |